NCT04925778View on ClinicalTrials.gov

Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

June 30, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

September 29, 2022

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

monomethyl fumarate

Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,

Sponsors
All Listed Sponsors
lead

Banner Life Sciences LLC

INDUSTRY